Clinical Trials Logo

Toxicity Due to Chemotherapy clinical trials

View clinical trials related to Toxicity Due to Chemotherapy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05927636 Recruiting - Cancer Clinical Trials

Systemic Treatment Related Toxicity Identified With a Smartphone APPlication Measuring Step Count

STAPPS
Start date: September 1, 2022
Phase:
Study type: Observational

The goal of this observational study is to investigate whether daily physical activities measured with a smartphone are related to the possible side effects or other physical complaints that arise as a result of cancer treatment. The investigators want to test whether the number of steps per day, both before and during treatment, are related to possible side effects or other physical complaints of the treatment using a smartphone. Knowledge about this relationship gives us possible starting points to prevent and/or reduce side effects and improve treatment outcomes. Additional research would then be needed. The investigators also want to investigate whether these daily measurements are feasible for patients undergoing treatment. Participation in the study involves measuring daily physical activity from the week before treatment until the first 3 months of treatment have been completed. This is done by tracking daily steps with patients own phone using the OncoSTAPP application.

NCT ID: NCT04999332 Recruiting - Gastric Cancer Clinical Trials

Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer

LOTS
Start date: December 10, 2021
Phase: Phase 2
Study type: Interventional

The aim of the trial is to investigate the clinical efficacy and toxicity of perioperative chemotherapy with leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who receive a curative surgery.

NCT ID: NCT03199300 Recruiting - Clinical trials for Cardiovascular Morbidity

Investigating Cardiovascular Adverse Events Related to Cancer Treatment

InvestiCAT
Start date: December 12, 2017
Phase:
Study type: Observational

Cisplatin, anthracyclines, bleomycin and trastuzumab can cause severe cardiovascular or pulmonary toxicity. Why some patients are susceptible to extreme toxicity of cancer treatment is largely unknown. Unraveling extreme cardiovascular toxic responses in cancer patients may help understand the pathophysiology of cardiovascular toxicity of these agents and help in understanding the more subtle, long-term cardiovascular side effects that affect a larger part of cancer survivors. With induced pluripotent stem cells we will obtain patient-derived cells to recapitulate and mimic and study pathological (cardiovascular) responses and (cardiovascular) toxicity in vitro.

NCT ID: NCT02848807 Recruiting - Quality of Life Clinical Trials

Chemotherapy-related Toxicity, Nutritional Status and Quality of Life

Start date: September 2014
Phase: N/A
Study type: Interventional

Determine whether nutritional support with high protein ONS in adult oncologic patients in the first step of cancer cachexia - asymptomatic precachexia, influence on the toxicity of systemic therapy.

NCT ID: NCT02781155 Recruiting - Breast Neoplasms Clinical Trials

Limiting Chemotherapy Side Effects by Using Moxa

Start date: February 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This study investigates whether it is feasible to teach cancer patients undergoing chemotherapy to self-administer daily moxibustion to reduce chemotherapy side effects. Moxibustion is a therapy used in traditional Chinese medicine that uses heat.

NCT ID: NCT01892852 Recruiting - Multiple Myeloma Clinical Trials

Acupuncture for Chemotherapy-induced Peripheral Neuropathy

Start date: June 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether acupuncture can be effective for chemotherapy-induced peripheral neuropathy in lymphoma or multiple myeloma patients.

NCT ID: NCT01493011 Recruiting - Clinical trials for Non-small Cell Lung Cancer Stage IIIB

Chemotherapy Combined With Whole-body Hyperthermia to Treat Stage IIIB/IV Non Small Cell Lung Cancer

WBH&NSCLC
Start date: November 2011
Phase: N/A
Study type: Interventional

Millions of patients die of non-small cell lung cancer (NSCLC) every year. There are several methods to treat NSCLC, including surgery, chemotherapy, radiotherapy and bioimmuotherapy. Recently, hyperthermia therapy has played an important role in neoplasm therapy. It has showed some effect in NSCLC both in animal experiment and clinical practice, yet there is little literature about Whole-body Hyperthermia (WBH) with neoplasm. The investigators decides to develop this randomized contrasted multicenter clinical study to testify to the effect of chemotherapy combined with WBH to treat stage IIIB/IV Non Small Cell Lung Cancer (NSCLC).